Nicole Luckschander-Zeller

Prof. Nicole Luckschander-Zeller

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2014 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
EHE. Haas
E. Haas
BRB.C. Rütgen
B.C. Rütgen
WGWilhelm Gerner
Wilhelm Gerner
BRB. Richter
B. Richter
ATA. Tichy
A. Tichy
NLNicole Luckschander-Zeller
Nicole Luckschander-Zeller
Background: Many dogs suffering from inflammatory bowel disease (IBD) are presented to veterinary clinics. These patients are diagnosed based on a history of chronic gastrointestinal signs and biopsy-confirmed histopathologic intestinal inflammation. Intestinal intraepithelial lymphocytes (IEL) are part of the first line of defense in the gastrointestinal immune system. Alterations in IEL subsets may play a role in the pathogenesis of IBD. Hypothesis: The aim of this study was to characterize the phenotypes of IEL in dogs with IBD compared with healthy control dogs. Animals: Intestinal intraepithelial lymphocytes subpopulations of control dogs (n = 5) obtained from endoscopic biopsies (EB) were compared to those obtained from full thickness biopsies (FTB) on the same day. In addition, the phenotypes of IEL from FTB of control dogs (n = 10) were compared with EB of IBD dogs (n = 10). Each participant was scored clinically using the canine inflammatory bowel disease activity index (CIBDAI), and all samples were graded histopathologically. Three-color flow cytometry of isolated IEL was performed using monoclonal antibodies against T- and B-lymphocyte subpopulations. Results: No significant differences in the composition of IEL subpopulations were found in control dogs based on method of biopsy. The IBD dogs had significantly higher CIBDAI and histopathologic scores compared with control dogs and their IEL contained a significantly higher frequency TCRγδ T-cells. Conclusions and Clinical Importance: Endoscopic biopsies provide suitable samples for 3-color flow cytometry when studying canine intestinal IEL and IBD patients show significant changes of major T-cell subsets compared to healthy control dogs.

1 August 2019 in Veterinary Immunology and Immunopathology
Verified
Journal Article
Closed access
NLNicole Luckschander-Zeller
Nicole Luckschander-Zeller
SHSabine E. Hammer
Sabine E. Hammer
BRBarbara C. Ruetgen
Barbara C. Ruetgen
ATAlexander Tichy
Alexander Tichy
JTJohann G. Thalhammer
Johann G. Thalhammer
IBIwan Burgener
Iwan Burgener

16 July 2024 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
PDF file
NLNicole Luckschander-Zeller
Nicole Luckschander-Zeller
BGBettina Giani
Bettina Giani
PDPavlos G. Doulidis
Pavlos G. Doulidis
HPHanna D. Plickert
Hanna D. Plickert
ATAlexander Tichy
Alexander Tichy
IBIwan A. Burgener
Iwan A. Burgener
Introduction: Canine Parvovirus 2 (CPV-2) infection poses a significant global health risk to susceptible dogs. Hypocobalaminemia, defined as reduced serum cobalamin (CBL) concentrations, is a recognized complication in chronic enteropathies in adult dogs but remains poorly understood in the context of acute enteropathies, especially in young dogs. The aim of this study was to investigate the frequency and severity of hypocobalaminemia in young dogs with parvovirus enteritis and evaluation of CBL as a predictor of outcome.Materials and methods: Thirty client-owned dogs diagnosed with parvovirus infection and thirty healthy controls were enrolled. Clinical, hematological, and biochemical tests, including CBL and serum methylmalonic acid (MMA) concentrations, were assessed.Results: Results indicated a significantly higher prevalence of hypocobalaminemia in dogs with parvovirus enteritis compared to healthy controls, as well as a significant correlation with a disease severity score. Moreover, survivors demonstrated higher CBL concentrations than non-survivors, suggesting an eventual prognostic value of CBL status. However, parenteral CBL supplementation showed no significant effect on serum CBL or MMA concentrations, highlighting potential challenges in CBL uptake at the cellular level.Discussion: Hypocobalaminemia in this population is caused by multiple factors such as reduced nutritional absorption, gastrointestinal losses, and increased metabolic demands. Further research is needed to develop tailored management strategies, evaluate the effectiveness of CBL supplementation, and understand the mechanisms behind hypocobalaminemia in parvovirus infection.

3 December 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
VSVerena Steiner
Verena Steiner
ARAdriana Cabal Rosel
Adriana Cabal Rosel
WRWerner Ruppitsch
Werner Ruppitsch
FAFranz Allerberger
Franz Allerberger
AVAlejandra Carranza Valencia
Alejandra Carranza Valencia
FKFrank Künzel
Frank Künzel
Infectious endocarditis (IE) in dogs is often associated with a high mortality rate as diagnostic work-up as well as antibiotic treatment might be challenging. The present case describes bacteremia in a dog caused by Achromobacter xylosoxidans, leading to an infectious endocarditis. Achromobacter xylosoxidans (A. xylosoxidans) is an aerobic Gram-negative rod-shaped bacterium, which has been associated with multiple nosocomial opportunistic diseases in human medicine. One such manifestation of A. xylosoxidans infection is endocarditis. A. xylosoxidans infections are challenging to treat due to the reduced effectiveness of a wide range of antimicrobial agents. To date, only a few case reports of infections with A. xylosoxidans in animals have been described. This is the first case report of A. xylosoxidans endocarditis in a dog. Whole-genome sequencing was performed to determine the sequencing type and to gain more information about this bacterium regarding its intrinsic resistance genes. With this case report, we seek to increase awareness of A. xylosoxidans as an opportunistic nosocomial pathogen in dogs and to provide a short summary regarding the current state of general knowledge and known resistance patterns.

2 September 2026 in Animals
Verified
Journal Article
Open access
PDF file
Lisa-Maria KulmerLisa-Maria Kulmer
Lisa-Maria Kulmer
PDPavlos Georgios Doulidis
Pavlos Georgios Doulidis
IBIwan Burgener
Iwan Burgener
NLNicole Luckschander-Zeller
Nicole Luckschander-Zeller
Background: Non-associative immune-mediated hemolytic anemia (IMHA) is uncommon in cats and carries substantial mortality. Glucocorticoids are first-line treatment, and cyclosporin A (CsA) is frequently added, but data on the clinical course and long-term outcome are limited. We describe clinical findings, treatment, adverse events and outcome in cats with non-associative IMHA. Methods: In this retrospective observational single-center study (October 2014–October 2024), 37 cats diagnosed by the 2019 ACVIM consensus criteria were included; 15 received prednisolone alone (PG) and 22 prednisolone combined with CsA (CPG), allocated at the clinician’s discretion. Between-cohort comparisons are exploratory. Results: Cats in the CPG cohort presented with more severe anemia. Overall mortality was 24.3%, with all deaths within four weeks; survival to discharge was 13/15 (PG) and 19/22 (CPG). Median follow-up was 50 [8–430] and 70 days [12–330]. Two cats achieved sustained treatment-free remission of 4.2 and 1.9 years. Five cats relapsed, four while receiving ongoing immunosuppression. Conclusions: Most cats survived the acute phase but required prolonged immunosuppression, and sustained treatment-free remission was uncommon. Relapses occurred predominantly during ongoing therapy rather than after discontinuation. Because CsA was used preferentially in more severely affected cats, comparative efficacy cannot be assessed and remains to be addressed prospectively.

8 July 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
CRCarolina Frizzo Ramos
Carolina Frizzo Ramos
PDPavlos Georgios Doulidis
Pavlos Georgios Doulidis
UKUrsula Susanne Kolm
Ursula Susanne Kolm
IBIwan Burgener
Iwan Burgener
Franziska Roth-WalterFranziska Roth-Walter
Franziska Roth-Walter
NLNicole Luckschander-Zeller
Nicole Luckschander-Zeller
Cardiac disease represents a major cause of morbidity and mortality in dogs. In human cardiology, iron deficiency is a highly prevalent and clinically relevant comorbidity, contributing to exercise intolerance, symptom burden, and impaired quality of life independently of anemia, while correction with intravenous iron improves function and reduces hospitalization. Iron metabolism in dogs remains poorly characterized and typically considered only in the context of anemia. This study investigated iron metabolism and its regulatory pathways in dogs with cardiac disease, assessing whether alterations in iron handling and availability consistent with an iron-restricted phenotype are present. Hematologic indices, serum iron, total and unsaturated iron-binding capacity (TIBC, UIBC), ferritin, hepcidin, ceruloplasmin, C-reactive protein, and albumin were evaluated in 61 dogs comprising healthy controls, and dogs either with compensated cardiac disease (CCD group) or presenting acute decompensated congestive heart failure (ADCHF group). Dogs with cardiac disease exhibited evidence of systemic inflammation, reduced hematocrit, increased red blood cell distribution width, and decreased circulating iron. Both cardiac groups showed reduced TIBC and UIBC, suggesting decreased transferrin availability and reduced iron transport capacity, whereas ferritin concentrations did not differ between groups. Hepcidin concentrations were lower in CCD and not increased in ADCHF patients, suggesting complex and non-uniform regulation of iron homeostasis rather than a classic hepcidin-driven inflammatory pattern. In dogs with ADCHF, iron-binding capacity was independently associated with indices of cardiac remodeling, and additional correlation between inflammatory markers and iron-related parameters supported an interaction between inflammation, iron handling, and disease severity.